You are reading the web version of STAT’s pop-up newsletter, "AACR in 30 Seconds"—a guide to the annual meeting of the American Association for Cancer Research. Click here to subscribe.

The massive AACR annual meeting is drawing to a close. We hope to see you at our virtual event on Tuesday evening. Clearly, Revolution Medicines and KRAS have taken center stage at this year's conference. Last year, the AACR meeting largely revolved around the trajectory of cancer research funding under the Trump administration; this year, the new Director of the National Cancer Institute (NCI) sought to allay researchers' concerns. Read on!

Revolution Medicines' KRAS Drug Demonstrates Robust Efficacy.

Last week, researchers collaborating with the biotech firm Revolution Medicines announced startling news: compared to chemotherapy, the investigational drug daraxonrasib more than doubled the survival time of patients with second-line pancreatic cancer—though this meant the median survival for this dreaded disease was extended by only six months.